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Pear-Infrared Spectroscopy for the
etection of Vulnerable Coronary Artery Plaques
ay D. Caplan, SB, MBA,* Sergio Waxman, MD,†‡ Richard W. Nesto, MD,†§ James E. Muller, MD*
urlington and Boston, Massachusetts
This review describes efforts to use near-infrared (NIR) spectroscopy to identify chemical
components of coronary artery plaques as a means to assess vulnerability. Near-infrared
spectroscopy has been well-validated by the physical sciences as a method to characterize
chemical composition of various bio-materials and could be ideal to detect vulnerable
coronary plaques in patients. Recent studies in aortic and coronary artery autopsy specimens
have confirmed the ability of the technique to identify lipid-rich thin-cap fibroatheromas
through blood. A catheter-based system has been developed to address the challenges—of
access to the coronary artery, blood, motion, and the need to scan—that must be overcome
for use in patients. Initial clinical experience in six patients with stable angina demonstrates
that high-quality NIR spectra can be safely obtained. Additional studies are planned to
validate the ability of the technique to identify lipid-rich coronary artery plaques and
ultimately link chemical characterization with subsequent occurrence of an acute coronary
syndrome. (J Am Coll Cardiol 2006;47:C92–6) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.045Cardiology Foundation
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dear-infrared (NIR) spectroscopy—a technique routinely
sed in the physical sciences to determine the chemical
omposition of substances—is under intensive study as a
otential tool to identify vulnerable atherosclerotic plaque.
he impetus for this work is the high likelihood that
laques with a distinct chemical composition (i.e., inflamed
hin-cap fibroatheromas [TCFAs]) represent vulnerable
laques that are likely to cause acute coronary syndromes
1). The goal of intracoronary NIR spectroscopy is to
rovide a “chemogram” of the wall of the artery that will
erve as an index of vulnerability.
Because of the high level of development of NIR spec-
roscopy for other applications, there was little doubt that it
ould be used in an ex vivo setting to determine the
hemical composition of tissue. Numerous studies from
ultiple groups have now confirmed this expectation, as
escribed in this review.
Despite these encouraging ex vivo data, major questions
emained as to whether high-quality spectra can be safely
btained from the coronary arteries of living patients in
hom problems of access, penetration of blood, cardiac
otion, and need for a scanning capability must be over-
ome. New developments, however, in laser technology,
ber optics, and chemometric analysis of spectra make
ntra-coronary NIR spectroscopy an approach that might
e of considerable utility for the detection of vulnerable
laque.
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ear-infrared spectroscopy takes advantage of the fact that
ifferent substances absorb and scatter NIR light (wave-
engths from 800 to 2,500 nm) to different degrees at
arious wavelengths. An NIR spectrometer emits light into
sample and measures the proportion of light that is
eturned over a wide range of optical wavelengths. The
eturn signal is then plotted as a graph of absorbance
y-axis) at different wavelengths (x-axis) called a spectrum.
igure 1 shows the spectrum of cholesterol, a molecule of
reat interest for vulnerability detection, and other pure
ubstances.
Absorbance is caused by the loss of NIR light when it
nteracts with certain molecular bonds (CH, OH, NH, and
thers) whose vibrational frequency is identical to the
requency of the incoming light. The absorbance spectrum
f a biologic tissue, which is composed of thousands of
ifferent chemical entities, is determined by the net result of
he absorbances of its individual chemical components.
Scattering of NIR light, which differs from absorbance,
esults from deflections of the light by cellular and extracel-
ular structures. A common example of scattering is the
edirection of visible light by water droplets when a car
eadlight is aimed into fog.
Scattering is both a help and a hindrance to tissue
pectroscopy. Because scattering varies as a function of
avelength and is different for different tissue components,
he degree of scattering might provide valuable information
bout the sample. Scattering also permits light to travel an
ndirect path from the source, through the tissue, and back
o the detector. These properties aid the spectroscopic
etermination of chemical composition.
Scattering by tissue, however, also causes the loss of mostf the NIR light emitted, thereby creating a need to increase
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btain adequate signal-to-noise in the return signal.
To identify an unknown tissue type, NIR spectra of
nown tissue samples are first correlated with characteristic
eatures of the tissue measured by a reference method such
s biochemical analysis or histology. Multivariate mathe-
atical techniques, such as principal component regression
nalysis, are then used to identify spectra associated with the
issue of interest. These algorithms are then applied to NIR
pectra of unknown samples, to identify their chemical
omposition of the sample. These methods are part of a
amily of analytical techniques known as “chemometrics.”
As previously noted, NIR spectroscopy is in routine use in
isciplines such as agriculture, chemistry, food processing,
harmaceuticals, and astronomy (2). Specific uses include
he measurement of octane in gasoline, alcohol content in
everages, and composition of pharmaceuticals. An impor-
ant medical application has been the use of differential NIR
bsorbance of hemoglobin and oxyhemoglobin to determine
xygen saturation in tissues (3–5).
Near-infrared spectroscopy can provide simultaneous,
ulticomponent, nondestructive chemical analysis of bio-
ogic tissue with an acquisition time of 1 s (6). Further-
ore, no sample preparation is required, and physical,
iologic, and molecular information can be derived. It has
een documented that a large range of biologic constituents
an be identified using NIR algorithms (6), and signals can
e obtained from structures millimeters- to centimeters-
eep relative to the tissue surface.
HARACTERIZATION OF ATHEROSCLEROTIC PLAQUE
he use of NIR spectroscopy for characterization of ath-
rosclerotic plaque was initiated in 1993 by Cassis and
odder (7). It was first shown that NIR spectra could
ccurately characterize low-density lipoprotein cholesterol
ccumulation in hypercholesterolemic rabbit aortas (7).
ear-infrared spectroscopy was then used in humans to
mage lipid content in carotid plaques exposed at the time of
urgery (6). After surgery, ex vivo NIR scanning was
erformed on the excised plaque, and spectra were shown to
redict lipoprotein composition as determined by gel elec-
rophoresis.
The early reports that NIR spectroscopy could be useful
or characterizing plaque have been supported by similar
ndings from other groups. In 1999, Jaross et al. (8)
ompared cholesterol content determined by NIR spectros-
opy versus that determined by reversed-phase, high-
Abbreviations and Acronyms
IVUS  intravascular ultrasound
NIR  near-infrared
TCFA  thin-cap fibroatheromaressure liquid chromatography in human aorta specimens. whigh correlation coefficient (0.96) was observed. The
ame group later reported that the cholesterol-to-collagen
atio could also be accurately quantified by NIR (9).
In a study of recently excised human carotid plaque
amples, Wang et al. (10) found a high correlation between
irect ex vivo measurements of lipid/protein ratios and
esults obtained with a NIR spectrometer fitted with a
ber-optic probe.
DENTIFICATION OF INFLAMED
CFAs IN AUTOPSY SPECIMENS
he use of NIR spectroscopy for detection of an inflamed
CFA, a particular form of atherosclerotic plaque suspected
o be likely to rupture and cause an acute coronary syn-
rome, was first reported by Moreno et al. (11) in 2002.
pectra were collected from 199 human aortic autopsy
amples with a commercial NIR spectrophotometer (Model
500, FOSS NIRSystems, Laurel, Maryland). The samples
ere fixed in formalin and studied without motion and in
he absence of blood. The spectra were then compared with
istologic findings suspected to be associated with vulnera-
le plaques. An algorithm was constructed with 50% of the
amples as a calibration set. The algorithm was then tested
n a validation set to determine its ability to identify
igh-risk features as determined by histology. Sensitivity
nd specificity were 90% and 93% for lipid pool, 77% and
3% for thin cap, and 84% and 91% for presence of
nflammatory cells, respectively.
These studies were then extended from aortic to coronary
issue, and similar results were obtained. Moreno et al. (12),
ith the use of the same commercial NIR spectrophotom-
ter (FOSS NIRSystems), performed NIR spectroscopy on
xed human coronary samples collected from 167 sections
f 45 arteries. Neither motion nor blood was present.
pectral findings were compared with histologic measure-
ents of lipid area. An algorithm was again constructed
ith 50% of the samples as a calibration set. The algorithm
igure 1. Near-infrared spectra of various pure substances possibly related
o plaque vulnerability.as then tested on a validation set for its ability to detect
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he detection of lipid-rich coronary plaques were 83% and
4%, respectively.
In summary, seven studies from three different groups
ave documented conclusively that NIR spectroscopy, in the
bsence of difficulties posed by motion and blood, can
ccurately identify important features of atherosclerotic
laques suspected to represent plaque vulnerability (6–12).
PPROACHES TO OVERCOME THE OBSTACLES TO
ERFORMANCE OF CLINICAL NIR SPECTROSCOPY
he coronary artery of a beating heart is a difficult environ-
ent for the performance of spectroscopy. Four obstacles
ust be addressed before results similar to those of ex vivo
tudies can be achieved. First, NIR light must be delivered
o the artery and collected with minimal risk to the patient.
econd, the undesirable effect of blood on the signal must be
vercome. Third, the effect of coronary motion on spectra
ust be managed. Fourth, a scan of all major coronary
rteries is needed for clinical use.
pectroscopic access to the human coronary artery. A
ultidisciplinary team (InfraReDx Inc., Burlington, Mas-
achusetts) has constructed a small (3.2-F) coronary artery
atheter containing fibers to deliver and collect infrared light
ithin the coronary artery (Fig. 2). The lateral spatial resolu-
igure 2. The 3.2-F near-infrared spectroscopy catheter, showing ports for
elivery and collection of light. The ruler is marked in centimeters.
igure 3. Figures of the porcine xenograft model and spectral results, test
nd motion. The spectroscopy catheter was placed in the perfused human co
reparation. The system was able to detect signals through blood from a spectral
ithout intervening blood or motion.ion of the device is approximately 1 mm in radius (13). The
atheter is similar to an intravascular ultrasound (IVUS)
atheter, which has an excellent safety record. As described in
he following section, it has been used successfully in patients,
ndicating that the problem of access has been solved.
eduction of the effect of blood on acquisition of the
pectral signal. Tests were conducted in autopsy specimens
o determine if NIR spectroscopy could accurately identify
ipid-rich plaques through blood. With the use of a Foss
pectrometer, spectra were collected from 63 specimens
rom 26 unfixed human aorta samples. The system identi-
ed large lipid-rich plaques (sensitivity, 88%, and specificity,
9%) through up to 3 mm of blood (14) and could classify
hem on the basis of cap thickness (15).
inimizing the effect of coronary artery motion on
cquisition of the spectral signal. An ultra-fast system
as created to minimize the effect of cardiac motion on NIR
ignals. This system uses a specialized laser that can obtain
pectra within 6 ms by scanning only a limited number of
avelengths. Although the narrower waveband provides
ewer spectral features for analysis, it is capable of adequate
erformance, as judged by studies performed on ex vivo
uman coronaries in the presence of blood (14). Approxi-
ately 3,000 arterial locations from 30 hearts were analyzed
y NIR spectroscopy and histology. The area under the
urve of the receiver operating characteristics curve for
dentification of TCFA and disrupted plaques was 0.74.
To evaluate performance of the system during cardiac
otion, a human coronary autopsy specimen was attached
o the surface of a beating pig’s heart and connected to the
orcine circulation (16). The ability of the NIR catheter
placed in the xenograft lumen) to identify the presence or
bsence of a Teflon target attached to the surface of the graft
as determined (17) (Fig. 3). The NIR system correctly
dentified the presence or absence of the target in all cases,
espite cardiac motion.
evelopment of the ability to scan the coronary artery. A
ystem was developed to rotate and pull the optical probe
ack so that an entire artery could be scanned. This system
e ability of the near-infrared (NIR) system to detect signal despite blood
ry artery attached to the surface of a beating porcine heart in an open-chesting th
ronatarget on a beating heart similar to those obtained directly from the target
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lood-filled phantom model of the coronary artery. The system
ccurately identified all eight simulated TCFAs (Fig. 4) in a
eproducible manner (InfraReDx Inc., unpublished data on
le, October 2005). The phantom study does not prove that
ipid-rich plaques can be identified in patients—for that
oal, clinical studies are required.
igure 4. Figures of the phantom simulating the human coronary artery a
laced in the blood-filled lumen of the phantom and then rotated and pulle
hows the results of the scan, with distance along the lumen on the x-axis
uccessfully detected all eight targets.
igure 5. Demonstration of spectral findings in the left anterior descendin
ata, on file InfraReDx, Inc., Burlington, Massachusetts). A spectral sca
nalysis was performed of all spectra to determine the shapes (principal com
canned the artery. The top graph shows a shape of biologic interest tha
etected in a sample of blood only. The bottom graph shows the amount of
nd rotated (y-axis) within the coronary artery. The white areas indicate loc
nterpretation of the spectral findings is not yet complete and a validated
he near-infrared (NIR) system to obtain relevant NIR signals from the corona
lood. LV  loading vector; PCA  principal component analysis.LINICAL EXPERIENCE WITH
HE NIR SPECTROSCOPY SYSTEM
n 2001, Dr. Richard Nesto tested a prototype device in
atients undergoing coronary stenting at the Lahey Clinic
n Burlington, Massachusetts (18). No device-related ad-
erse events occurred, but substantial motion artifact was
n-cap fibroatheroma targets. The near-infrared spectroscopy catheter was
k in a test of detection of the spatially resolved targets. The bottom panel
arc of rotation on the y-axis. As indicated by the yellow signal, the scan
D) coronary artery of a patient with stable angina pectoris (unpublished
he LAD was performed during percutaneous coronary intervention. An
ts) that contribute to the spectra obtained in each data point as the catheter
tributed to the individual spectra in varying degrees. The shape was not
hape that was detected at each pixel as the catheter was pulled back (x-axis)
s from which the shadow created by the guide wire was removed. Although
thm has not yet been applied to the data, the display shows the ability ofnd thi
d bac
andg (LA
n of t
ponen
t con
that s
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algoriry artery of a patient, despite the presence of cardiac motion and flowing
p
t
W
o
a
t
R
s
h
D
s
p
c
r
i
t
N
c
p
i
l
u
s
d
c
s
i
i
R
I
j
R
1
1
1
1
1
1
1
1
1
C96 Caplan et al. JACC Vol. 47, No. 8 Suppl C
NIR Spectroscopy Detection of Vulnerable Coronary Artery Plaques April 18, 2006:C92–6resent. In August 2005, the new ultrafast NIR system was
ested in six patients at the Lahey Clinic by Dr. Sergio
axman and Dr. Nesto. The trial confirmed safety (clinical
utcomes did not differ from those expected with stenting
nd IVUS usage) and demonstrated that signals obtained in
he artery differ from those obtained in blood alone (Infra-
eDx Inc., unpublished data, August 2005) (Fig. 5).
Additional studies are needed to test the ability of NIR
pectroscopy to identify lipid-rich plaques in patients (as it
as in autopsy specimens). If such studies are positive, in
ecember 2006, InfraReDx Inc. will seek to make the
ystem available to clinicians for the detection of lipid-rich
laques. The cost of the console will be less than an IVUS
onsole, and the costs of the catheters will be within the
ange of special-use catheters already purchased by catheter-
zation laboratories. Additional optimization strategies include
he construction of a non-rotating catheter, the combination of
IR with other modalities such as ultrasound in a single
atheter, and the use of molecular imaging agents.
Future studies will be required to determine if, as ex-
ected, lipid-rich plaques have a higher likelihood of caus-
ng cardiac events. If the NIR system is capable of detecting
ipid-rich plaques in vivo that are vulnerable, it might be
seful for determining the value of placing a drug-eluting
tent at a lesion producing an intermediate (50% to 60%)
egree of stenosis and for the identification of patients who
ould be randomized to a pharmaceutical agent designed to
tabilize vulnerable plaques or conventional therapy. Success
n either treatment study would establish the value of
dentification and treatment of vulnerable plaques.
eprint requests and correspondence: Jay D. Caplan, InfraReDx
nc., 34 Third Avenue, Burlington, Massachusetts 01803. E-mail:
caplan@infraredx.com.
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